Reneo Pharmaceuticals (RPHM) Stock Forecast, Price Target & Predictions
RPHM Stock Forecast
Reneo Pharmaceuticals stock forecast is as follows: a rating consensus of 'Buy', based on 1 wall street analysts offering a 1-year stock forecast.
RPHM Analyst Ratings
According to 1 Wall Street analysts, Reneo Pharmaceuticals's rating consensus is 'Buy'. The analyst rating breakdown for RPHM stock is 0 'Strong Buy' (0.00%), 1 'Buy' (100.00%), 0 'Hold' (0.00%), 0 'Sell' (0.00%), and 0 'Strong Sell' (0.00%).
Analyst Ratings Upgrades/Downgrades
| Date | Company | Previous Rating | New Rating | Rating Change |
|---|---|---|---|---|
| May 17, 2022 | Piper Sandler | Overweight | Overweight | Hold |
Reneo Pharmaceuticals's last stock rating was published by Piper Sandler on May 17, 2022. The company gave RPHM a "Overweight" rating, the same as its previous rate.
Reneo Pharmaceuticals Financial Forecast
Reneo Pharmaceuticals Revenue Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | |
|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - |
| Avg Forecast | $15.96M | $7.97M | - | - | $100.25K | $27.25K | - |
| High Forecast | $15.96M | $7.97M | - | - | $100.25K | $27.25K | - |
| Low Forecast | $15.96M | $7.97M | - | - | $100.25K | $27.25K | - |
| # Analysts | - | - | - | - | - | - | - |
| Surprise % | - | - | - | - | - | - | - |
Reneo Pharmaceuticals's average Quarter revenue forecast for undefined based on undefined analysts is $NaN, with a low forecast of $NaN, and a high forecast of $NaN. RPHM's average Quarter revenue forecast represents a NaN% decrease compared to the company's last Quarter revenue of $NaN (undefined).
Reneo Pharmaceuticals EBITDA Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | |
|---|---|---|---|---|---|---|---|
| # Analysts | - | - | - | - | - | - | - |
| EBITDA | - | - | - | - | - | - | - |
| Avg Forecast | - | - | - | - | - | - | - |
| High Forecast | - | - | - | - | - | - | - |
| Low Forecast | - | - | - | - | - | - | - |
| Surprise % | - | - | - | - | - | - | - |
undefined analysts predict RPHM's average Quarter EBITDA for undefined to be $NaN, with a high of $NaN and a low of $NaN. This is NaN% lower than Reneo Pharmaceuticals's previous annual EBITDA (undefined) of $NaN.
Reneo Pharmaceuticals Net Income Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | |
|---|---|---|---|---|---|---|---|
| # Analysts | - | - | - | - | - | - | - |
| Net Income | - | - | - | - | - | - | - |
| Avg Forecast | $-6.35M | $-10.34M | $-16.82M | $-18.83M | $-2.34M | $-2.34M | $-3.34M |
| High Forecast | $-6.35M | $-10.34M | $-16.82M | $-18.83M | $-2.34M | $-2.34M | $-3.34M |
| Low Forecast | $-6.35M | $-10.34M | $-16.82M | $-18.83M | $-2.34M | $-2.34M | $-3.34M |
| Surprise % | - | - | - | - | - | - | - |
Reneo Pharmaceuticals's average Quarter net income forecast for undefined is $NaN, with a range of $NaN to $NaN. RPHM's average Quarter net income forecast represents a NaN% decrease compared to the company's last Quarter net income of $NaN (undefined).
Reneo Pharmaceuticals SG&A Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | |
|---|---|---|---|---|---|---|---|
| # Analysts | - | - | - | - | - | - | - |
| SG&A | - | - | - | - | - | - | - |
| Avg Forecast | - | - | - | - | - | - | - |
| High Forecast | - | - | - | - | - | - | - |
| Low Forecast | - | - | - | - | - | - | - |
| Surprise % | - | - | - | - | - | - | - |
Reneo Pharmaceuticals's average Quarter SG&A projection for undefined is $NaN, based on undefined Wall Street analysts, with a range of $NaN to $NaN. The forecast indicates a NaN% fall compared to RPHM last annual SG&A of $NaN (undefined).
Reneo Pharmaceuticals EPS Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | |
|---|---|---|---|---|---|---|---|
| # Analysts | - | - | - | - | - | - | - |
| EPS | - | - | - | - | - | - | - |
| Avg Forecast | $-0.19 | $-0.31 | $-0.50 | $-0.56 | $-0.07 | $-0.07 | $-0.10 |
| High Forecast | $-0.19 | $-0.31 | $-0.50 | $-0.56 | $-0.07 | $-0.07 | $-0.10 |
| Low Forecast | $-0.19 | $-0.31 | $-0.50 | $-0.56 | $-0.07 | $-0.07 | $-0.10 |
| Surprise % | - | - | - | - | - | - | - |
According to undefined Wall Street analysts, Reneo Pharmaceuticals's projected average Quarter EPS for undefined is $NaN, with a low estimate of $NaN and a high estimate of $NaN. This represents a NaN% decrease compared to RPHM previous annual EPS of $NaN (undefined).
Reneo Pharmaceuticals Peer Comparison by Price Target
| Ticker | Company | Last Closing Price | Avg Price Target | Upside/Downside | Avg Rating |
|---|---|---|---|---|---|
| HEPA | Hepion Pharmaceuticals | $0.68 | $70.00 | 10194.12% | Buy |
| KZR | Kezar Life Sciences | $0.57 | $17.50 | 2970.18% | Buy |
| RPHM | Reneo Pharmaceuticals | $1.37 | $18.00 | 1213.87% | Buy |
| KRON | Kronos Bio | $0.95 | $7.63 | 703.16% | Buy |
| HOWL | Werewolf Therapeutics | $2.14 | $12.00 | 460.75% | Buy |
| PRME | Prime Medicine | $3.74 | $17.25 | 361.23% | Buy |
| NKTX | Nkarta | $5.65 | $21.60 | 282.30% | Buy |
| IMMX | Immix Biopharma | $1.85 | $7.00 | 278.38% | Buy |
| VIR | Vir Bio | $7.87 | $26.60 | 237.99% | Buy |
| CNSP | CNS Pharmaceuticals | $0.15 | $0.50 | 233.33% | - |
| EWTX | Edgewise Therapeutics | $16.86 | $48.00 | 184.70% | Buy |
| ADPT | Adaptive Bio | $4.59 | $12.33 | 168.63% | Hold |
| CELC | Celcuity | $15.14 | $31.50 | 108.06% | Buy |
| APLS | Apellis Pharmaceuticals | $36.31 | $75.38 | 107.60% | Buy |
| CGEM | Cullinan Oncology | $16.93 | $32.00 | 89.01% | Buy |
| CCCC | C4 Therapeutics | $6.36 | $11.33 | 78.14% | Hold |
| LEGN | Legend Biotech | $51.29 | $78.78 | 53.60% | Buy |
| RPRX | Royalty Pharma | $28.26 | $43.33 | 53.33% | Buy |
| DNA | Ginkgo Bioworks | $6.23 | $7.34 | 17.82% | Buy |
| SMMT | Summit Therapeutics | $29.48 | $29.50 | 0.07% | Buy |
RPHM Forecast FAQ
Is Reneo Pharmaceuticals a good buy?
Yes, according to 1 Wall Street analysts, Reneo Pharmaceuticals (RPHM) is considered a 'Buy'. The rating consensus is based on 0 'Strong Buy' and 1 'Buy' recommendations, accounting for 100.00% of RPHM's total ratings.
What are Reneo Pharmaceuticals's analysts' financial forecasts?
Reneo Pharmaceuticals's analysts financial forecasts for the fiscal year (Dec 2024) are as follows: average revenue is $127.5K (high $127.5K, low $127.5K), average EBITDA is $0 (high $0, low $0), average net income is $-8.021M (high $-8.021M, low $-8.021M), average SG&A $0 (high $0, low $0), and average EPS is $-0.24 (high $-0.24, low $-0.24). RPHM's analysts financial forecasts for the fiscal year (Dec 2025) are as follows: average revenue is $23.93M (high $23.93M, low $23.93M), average EBITDA is $0 (high $0, low $0), average net income is $-52.334M (high $-52.334M, low $-52.334M), average SG&A $0 (high $0, low $0), and average EPS is $-1.566 (high $-1.566, low $-1.566).